CEL-SCI (NYSE:CVM) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

Equities researchers at StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

CEL-SCI Stock Performance

Shares of CVM opened at $0.29 on Tuesday. The stock has a 50-day moving average of $0.29 and a two-hundred day moving average of $0.51. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. The stock has a market cap of $24.16 million, a P/E ratio of -0.60 and a beta of 0.95. CEL-SCI has a one year low of $0.18 and a one year high of $2.39.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CEL-SCI stock. Geode Capital Management LLC boosted its stake in CEL-SCI Co. (NYSE:CVM – Free Report) by 9.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 612,861 shares of the company’s stock after acquiring an additional 53,879 shares during the quarter. Geode Capital Management LLC owned 0.96% of CEL-SCI worth $650,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

(Get Free Report)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

Read More